GeoVax to Provide Q1 2025 Financial Results and Strategic Update

Clinical-stage biotechnology company GeoVax Labs will release its first quarter 2025 financial results on May 1, 2025, followed by a comprehensive corporate update conference call. The announcement signals an important opportunity for investors and healthcare industry professionals to assess the company's progress in developing innovative vaccines and therapeutic interventions.

The conference call, scheduled for 4:30 p.m. ET, will provide detailed insights into GeoVax's key clinical programs, including its advanced COVID-19 vaccine candidate GEO-CM04S1 and oncological gene-directed therapy Gedeptin®. These programs represent significant potential advancements in addressing challenging medical needs for immunocompromised patients and cancer treatment.

GeoVax's COVID-19 vaccine program is currently investigating three distinct Phase 2 clinical trials. These trials explore the vaccine's potential as a primary immunization for patients with compromised immune systems, a booster for chronic lymphocytic leukemia patients, and an enhanced booster for individuals previously vaccinated with mRNA vaccines.

In the oncology domain, the company's Gedeptin® therapy has completed a multicenter Phase 1/2 clinical trial focused on advanced head and neck cancers, representing a promising avenue for targeted cancer treatment. Additionally, GeoVax is developing GEO-MVA, a vaccine targeting Mpox and smallpox, further demonstrating the company's commitment to addressing critical infectious disease challenges.

The upcoming financial results and corporate update will be crucial for healthcare investors, research professionals, and industry analysts seeking to understand GeoVax's strategic positioning and potential impact on vaccine and therapeutic technologies. The conference call represents an important moment for transparency and communication about the company's ongoing scientific and commercial developments.

Investors and interested parties can access the live audio webcast through GeoVax's investor relations website, with an archived version available for 90 days following the event. This accessibility underscores the company's commitment to open communication and stakeholder engagement.